The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Open accessAbstract
mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. We review the role of KRAS as a driver and therapeutic target in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This high prevalence is significant as it makes PDAC arguably the most RAS-addicted cancer, with substantial experimental evidence that mutant KRAS is essential for its growth [107].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, the KRAS isoform is mutated in 84% of all RAS-mutant cancers, with a near 100% mutation frequency in PDAC.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [107]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [9]
In the citing paper
“In pancreatic cancer, KRAS mutation is often the initiating genetic event leading to pancreatic intraepithelial neoplasms. Carcinogenesis and metastasis are stimulated by acquiring other mutations such as p53 (64%), SMAD4 (21%), and CDKN2A (17%) [63].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [63]
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [12]
In the citing paper
“the KRASG12C allele occurs in only 1.6% of PDAC cases, whereas the KRASG12D allele is present in greater than 40%, followed in frequency by KRASG12V and KRASG12R mutations74.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 4×
“Further, wholeexome deep-sequencing data of pancreatic cancer patients shows that 93% of the rare PIK3CA mutations co-occur with aKRASmutation, suggesting activated KRAS alone is not sufficient to effectively activate PI3K (Jones et al. 2008; Biankin et al. 2012; Sausen et al. 2015; Waddell et al. 2015; Witkiewicz et…”
BackgroundMethodInfluentialA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 881
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
Shi, Y., Du, J., Pan, W., Zhang, H., & Ba, Y. (2023) · journal of nutritional oncology · doi:10.1097/jn9.0000000000000008 · Cited by 5
A biology-informed similarity metric for simulated patches of human cell membrane
Bhatia, H., Thiagarajan, J. J., Anirudh, R., Jayram, T. S., Oppelstrup, T., Ingólfsson, H. I., Lightstone, F. C., & Bremer, P. (2022) · Machine Learning Science and Technology · doi:10.1088/2632-2153/ac8523 · Cited by 4
Pancreatic cyst fluid harboring a KRAS mutationPreprint
Al-Turkmani, M. R., Gordon, S. R., Smith, K. D., Tsongalis, G. J., & Liu, X. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003830 · Cited by 4
Peanlikhit, T., Aryal, U. K., Welsh, J. S., Shroyer, K. R., & Rithidech, K. N. (2024) · Research Square · doi:10.21203/rs.3.rs-4224843/v1 · Cited by 4
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Roy, J., Mouawad, R., Kyani, A., Hanafi, M., Xu, Y., Wen, B., Sun, D., & Neamati, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03159 · Cited by 3
The PIN1–p38–CtIP signalling axis protects stalled replication forks from deleterious degradation
Vivalda, F., Gatti, M., Manfredi, L., Dogan, H., Porro, A., Collotta, G., Ceppi, I., von Aesch, C., van Ackeren, V., Wild, S., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf278 · Cited by 3
Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review
Nandan, P. K., & Jayanthi, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02783-x · Cited by 4
Luo, Y., Tang, L., Zeng, Z., Trang, D., Mo, D., & Yang, Y. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102487 · Cited by 3
Paulsohn, M.-B., Frahnert, K. H., Schlösser, D., Oschwald, J., Kopp, W., Fang, X., Schneider, C., Contreras, C. T., Danieli‐Mackay, A., Ludewig, F., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08362-w · Cited by 5
Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond
Misirian, A., Pai, J., & Hanna, D. L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261432058 · Cited by 3
Guo, F., Tao, X., Wu, Y., Dong, D., Zhu, Y., Shang, D., & Xiang, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01806-w · Cited by 3
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Berginski, M. E., Jenner, M. R., Joisa, C. U., Loeza, G. H., Golitz, B. T., Lipner, M. B., Leary, J. R., Rashid, N. U., Johnson, G. L., Yeh, J. J., et al. (2024) · PeerJ · doi:10.7717/peerj.17797 · Cited by 7
Zhang, M., Chen, X., Zhou, Q., Guo, N., Cao, B., Zeng, H., Chen, W., & Sun, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.10.002 · Cited by 3
Gadwa, J., Yu, J., Piper, M., Knitz, M. W., Darragh, L. B., Olimpo, N. A., Corbo, S., Beynor, J. I., Neupert, B., Nguyen, A. T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010405 · Cited by 3
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Doi, T., Ishikawa, T., Moriguchi, M., & Itoh, Y. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf012 · Cited by 3
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Tang, E., Hu, Y., Cao, G., Nguyen, D.-T., Asby, N. W., Aboelella, N. S., Ruiz, H. A., Cai, X., Zhang, W., Zhao, Y. Q., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0691 · Cited by 3
Chen, L., Du, Y., Rao, S., Shi, Q., Cui, Y., Zhou, L., Xiong, C., Luo, Y., & Liu, Y. (2025) · ACS Sensors · doi:10.1021/acssensors.5c01158 · Cited by 3
KRAS: Structure, function, and development of anticancer drugs
Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3
Meti, N., Kelly, D., Allen, M. J., Lanys, A., Fazelzad, R., Ramjeesingh, R., Zogopoulos, G., Notta, F., Knox, J. J., Amir, E., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102310 · Cited by 3
Zhang, Z., Sun, W., Zeng, Z., & Lu, Y. (2022) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5758 · Cited by 3
Targeting K-Ras Mutations Show Promise Towards Ending Ras’s “Undruggable” Era
Adams, P. D., & Muhoza, D. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666221003124202 · Cited by 3
Gong, M., Zhang, B., Wang, X., Zhu, Z., Li, W., Han, L., Wu, Z., Ma, Q., Wang, Z., & Qian, W. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000154 · Cited by 3
“New Targets in Non–Small-Cell Lung Cancer”—RET, HER2, and KRAS
HALANI, V., Sharayah, A. M., Beck, B., & Patolia, S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202208-1596rr · Cited by 3
Precision Oncology in Hepatopancreatobiliary Cancer Surgery
Newhook, T. E., Tsai, S., & Meric‐Bernstam, F. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.026 · Cited by 3
Sychra, T., Spálenková, A., Balatka, S., Václavíková, R., Šeborová, K., Ehrlichová, M., Truksa, J., Sandoval-Acuña, C., Němcová‐Fürstová, V., Szabó, Á., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109044 · Cited by 3
Бегимбетова, Д., Burska, A. N., Baltabekova, A., Kussainova, A., Kukanova, А., Fazyl, F., Ibragimova, M., Manekenova, K., Макишев, А. К., Bersimbaev, R. I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052531 · Cited by 3
Functional distinction in oncogenic Ras variant activity in Caenorhabditis elegans
Lyu, H., & Chamberlin, H. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050577 · Cited by 3
Yi, M., Zhu, R., & Stephens, R. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207590 · Cited by 3
Validation of Isoform- and Mutation-Specific RAS Antibodies
Waters, A. M., & Der, C. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_5 · Cited by 3
Self-citationHufnagel, S., Xu, H., Colemam, M. F., Valdes, S. A., Liu, K. A., Hursting, S. D., & Cui, Z. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04367-2 · Cited by 3
Hollar, D. (2022) · Biosystems · doi:10.1016/j.biosystems.2022.104798 · Cited by 3
Cancer research and innovation: conceptualising a persistent anomaly
Xu, Y., & Gagliardi, D. (2023) · Innovation · doi:10.1080/14479338.2023.2204322 · Cited by 3
An integrated model for predicting KRAS dependency
(2023) · doi:10.1371/journal.pcbi.1011095 · Cited by 3
Redding, A., & Grabocka, E. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1304 · Cited by 3
Bortoletto, A. S., Yang, Z., Cardenas, M. G., Wang, M.-T., McCormick, F. P., & Parchem, R. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3064215/v1 · Cited by 3
Nakahashi, H., Oda, T., Shimomura, O., Akashi, Y., Takahashi, K., Miyazaki, Y., Furuta, T., Kuroda, Y., Louphrasitthiphol, P., Mathis, B. J., et al. (2024) · Journal of Oncology · doi:10.1155/2024/1529449 · Cited by 2
Antonova, L., Paramanthan, P., Falls, T. J., Wedge, M.-È., Mayer, J., Sekhon, H. S., McPherson, J. P., Denroche, R. E., Gallinger, S., Bell, J. C., et al. (2024) · Cancers · doi:10.3390/cancers16152721 · Cited by 2
Zhang, Y., Ma, Y., Zhang, K., Wang, Y., Sun, X., Kan, C., & Han, F. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001192 · Cited by 2
Precision Oncology in Pancreatic Cancer and Future Treatment Directions
Mahmasani, L. A., & O'Reilly, E. M. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.03.002 · Cited by 2
Wu, H., Zheng, K., & Han, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2518278 · Cited by 2
McDonald, R. A., Varela-Ramı́rez, A., & Ashley, A. K. (2025) · Biology · doi:10.3390/biology14080936 · Cited by 2
Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview
Citterio, C., Vecchia, S., Mordenti, P., Anselmi, E., Ratti, M., Guasconi, M., & Orlandi, E. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030026 · Cited by 2
Burge, R. A., Bialousow, L., McFall, T. B., Bamonte, L., Johnson, G., Smith, M., Vaena, S. G., Comte‐Walters, S., Ball, L. E., Berto, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0281 · Cited by 2
Lee, W., Woo, H.-M., Cho, J. H., & Kim, M. S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1718911 · Cited by 3
Maeda, C., Yusuke, O. N. O., TAKAHASHI, K., Mori, M., Suzuki, M., Tamamura, N., Sun, Y., Itoh, T., Tanaka, H., Kawabata, H., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf181 · Cited by 2
Joung, R. H., & Snyder, R. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-515560 · Cited by 2
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 2
Xiao, Y., Wang, W., Wang, G., Liu, Y., & Gong, J. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02987-2 · Cited by 2
Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
Kubiak, K., & Inkielewicz‐Stępniak, I. (2026) · Cancers · doi:10.3390/cancers18061001 · Cited by 2
Xue, S., Xu, H., Ma, J., Wang, Y., Lu, W., Cui, J., & Wang, L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218684 · Cited by 2
Jiao, J., Cheng, C., Cao, Z., Chen, L., & Chen, Z. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-3675-8 · Cited by 2
“The History of the Linear No-Threshold Model” video series
Gale, R. P., & Hoffman, F. O. (2022) · Health Physics · doi:10.1097/hp.0000000000001622 · Cited by 2
Significance of Tumor Microenvironment for Regulating Pancreatic Cancer
Ijichi, H. (2023) · Cancers · doi:10.3390/cancers15092482 · Cited by 3
Huang, H., Ji, P., & Peng, S. (2023) · Cureus · doi:10.7759/cureus.47641 · Cited by 2
Jusoh, A. R., Din, T. A. D. A. T., Abdullah‐Zawawi, M., Rahman, W. F. W. A., Nafi, S. N. M., Romli, R. C., Hashim, E. K. M., Patar, M. N. A. A., & Yahya, M. M. (2023) · PubMed Central · doi:10.22088/ijmcm.bums.12.3.257 · Cited by 2
Role of molecular biology in the management of pancreatic cancer
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Tarabay, A., Valéry, M., Fuerea, A. C., Pudlarz, T., Conroy, T., Hollebecque, A., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i7.2902 · Cited by 2
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Elhariri, A., Patel, J., Mahadevia, H. J., Albelal, D., Ahmed, A., Jones, J. C., Borad, M. J., & Babiker, H. M. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01088-3 · Cited by 2
The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations
Yi, M., Soppet, D. R., McCormick, F. P., & Nissley, D. V. (2024) · Scientific Reports · doi:10.1038/s41598-024-76591-8 · Cited by 2
LINC01559: roles, mechanisms, and clinical implications in human cancers
Zhang, S., Lan, X., & Lei, L. (2025) · Human Cell · doi:10.1007/s13577-025-01218-7 · Cited by 2
Peserico, G., Stornello, C., Tessari, M., Scapinello, A., Curtarello, M., Gruppo, M., Simoni, O. D., & Fantin, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178444 · Cited by 2
Precision Therapy of Pancreatic Cancer: From Bench to Bedside
Ciecielski, K. J., Berninger, A., & Algül, H. (2020) · Visceral Medicine · doi:10.1159/000509232 · Cited by 2
Mass Spectrometry Reveals High Levels of Hydrogen Peroxide in Pancreatic Cancer Cells
Liu, Q., Ge, W., Martínez‐Jarquín, S., He, Y., Wu, R., Stoffel, M., & Zenobi, R. (2023) · Angewandte Chemie · doi:10.1002/ange.202213703 · Cited by 2
Tarabay, A., Boilève, A., Smolenschi, C., Antoun, L., Valéry, M., Fuerea, A. C., Perret, A., Burtin, P. C., Cosconea, S., Belkhodja, H., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092569 · Cited by 2
Personalized medicine and new therapeutic approach in the treatment of pancreatic cancer
Azari, H., Nazari, E., Jamialahmadi, H., Khalili‐Tanha, G., Maftooh, M., Hassanian, S. M., Ferns, G. A., Khazaei, M., & Avan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19142-8.00010-3 · Cited by 2
Targeted Therapies for Pancreatic Cancer
Lee, M. S., & Pant, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_5 · Cited by 2
Liu, Y., Tang, S. C., Li, C. H., To, K. F., Li, B., Chan, S. L., Wong, C. H., & Chen, Y. (2024) · Cancer Science · doi:10.1111/cas.16286 · Cited by 2
Mehta, A., Hwang, W. L., & Weekes, C. D. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-2020-pda-05 · Cited by 2
Kim, E., Novak, L. C., Gheorghe, V., Bristow, C. A., & Hart, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.450004 · Cited by 2
Varesco, G., Luneau, E., Féasson, L., Lapole, T., & Rozand, V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.19.460938 · Cited by 2
Udayasuryan, B., Nguyen, T. T. D., Umaña, A., Ahmad, R. N., Roberts, L. M., Sobol, P., Jones, S. D., Munson, J. M., Slade, D. J., & Verbridge, S. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.19.469245 · Cited by 2
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal AdenocarcinomaPreprint
Ciecielski, K. J., Mulero‐Sánchez, A., Berninger, A., Cañas, L. R., Bosma, A. R., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472574 · Cited by 2
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 2
Bandi, D. S. R., Nagaraju, G. P., Sarvesh, S., Carstens, J. L., Foote, J. B., Graff, E. C., Fang, Y.-H. D., Keeton, A. B., Chen, X., Berry, K. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.04.616725 · Cited by 2
Synthetic gene circuits that selectively target RAS-driven cancers
Senn, G. V., Nissen, L., & Benenson, Y. (2026) · eLife · doi:10.7554/elife.104320 · Cited by 2
Signaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targets
McHugh, M. A., Ngo, N. T., Mitchell, A. C., Morand, S. M., Mack, S. T., Kaur, P., & Asea, A. A. A. (2023) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_29_2022 · Cited by 1
de Liyis, B. G., Mareska, V., AHMAD, C. A., WINDIARTO, A. C., & Indrayani, A. W. (2023) · Journal of Oncological Sciences · doi:10.37047/jos.2022-94097 · Cited by 1
Babayan, A., Витальевич, Л. Е., Lebedeva, A., Kuznetsova, O. A., Kravchuk, D., Grigoreva, T. V., Belova, E., Kavun, A., Mileyko, V., Tryakin, A. A., et al. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2376516 · Cited by 1
Milin, A. N., Giddens, J. P., & Marquez, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00007-3 · Cited by 1
Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer
Chung, W.-C., Zhang, S., Atfi, A., & Xu, K. (2024) · Oncogene · doi:10.1038/s41388-024-03226-7 · Cited by 1
Jhetam, Z., Martins-Furness, C., Slabber, C., Munro, O. Q., Nel, M., & Harmse, L. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112815 · Cited by 1
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Shin, D., Lee, D., Jeon, Y. J., Lee, K., Kim, Y., & Park, J. (2025) · Journal of Visualized Experiments · doi:10.3791/68076 · Cited by 1
Li, R., Zhang, G., Tao, Q., Wu, Z., Liu, X., Wang, R., Liu, L., Niu, Y., Du, K., Wu, R., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02200-3 · Cited by 1
Jenkins, C. B., Camero, A. L., Graff, B. T., Madduri, L. S. V., O’Connell, K. A., Hein, A. L., Smith, L. M., Enke, C. A., Dong, J., Hollingsworth, M. A., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03477-y · Cited by 1
Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition
Liu, C., Qi, J., Ye, D., Wang, S., Li, X., Guo, X., Li, X., Ding, M., & Liu, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117291 · Cited by 1
Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer
Alboreggia, G., Li, T., Prentiss, A. M., Udompholkul, P., Xia, F., Synold, T. W., Wu, J. F., Feng, M., Raoof, M., & Pellecchia, M. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201078 · Cited by 1
Nazir, N., Husnain, M., Waqar, A., Kanwal, M., Aziz, T. A., Al‐Hoshani, N., Mohamed, R. A. E. H., Alwethaynani, M. S., Al‐Joufi, F. A., & Hassan, R. N. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416526500353 · Cited by 1
Advances and Challenges in KRAS Mutation Detection and Clinical Implications
Mirlohi, M. S., Yousefi, T., Razaviyan, J., Nomiri, S., Pishbin, E., Shabani‐Rad, M., Ahmadian, M. R., & Salami, S. (2025) · Cancers · doi:10.3390/cancers18010031 · Cited by 1
Fu, M., Zhu, Q., Qi, J., Zhang, X., Wang, Z., Wang, J., Huang, X., Hu, Z., Wang, W., Hong, B., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09440-7 · Cited by 1
Pancreatic cancer: emerging small molecule pharmacotherapies
Pokora, B., Pokora, K., & Fichna, J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2657995 · Cited by 1
Artificial intelligence: Catalyzing a new era in pancreatic cancer cure
Wang, J., Luo, W., Zhang, M., Wang, Y., Ye, L., Qiu, J. U. N. T. A. O., Liu, Y., Weng, G., Liu, T., Cao, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218558 · Cited by 1
The emerging role of the Hippo signaling pathway in interorgan crosstalk
Song, G., Lee, C., & Jho, E. (2026) · FEBS Journal · doi:10.1111/febs.70587 · Cited by 1
Lee, J., Zhu, Y., & Tseng, H. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6c00091 · Cited by 1
Magnesium as a conformational gatekeeper of KRAS : Structural dynamics and therapeutic implications
Srinivasu, B. Y., Damerla, T. S., Stec, A., Zhou, Z., Engen, J. R., Westover, K. D., & Wales, T. E. (2026) · Protein Science · doi:10.1002/pro.70681 · Cited by 1
Kim, B., & Lee, J. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135682 · Cited by 1
Ma, H., Lu, H., Zhang, Z., Wang, J., Zhao, Q., Ding, Y., Wang, X., Zhang, W., Li, N., & Wang, S. (2026) · Discover Oncology · doi:10.1007/s12672-026-05562-4 · Cited by 1
Wang, Y., Zhang, Y., Wang, X., Zhao, W., Li, Q., Zhou, M., Liu, Y., Yi, X., He, J. I., Li, Y. P., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02712-8 · Cited by 1
Shi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.08.012 · Cited by 1
Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression
Kalfakakou, D., Cameron, D., Kawaler, E. A., Tsuda, M., Wang, L., Su, Q., Kim, S., Manolakos, E., Jing, X., Hajdu, C., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02779-5 · Cited by 7
Metadata
- Authors
- Waters, A. M., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-12-11
- Volume
- 8
- Issue
- 9
- Pages
- a031435
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC5995645
- OpenAlex
- W2771729549
- Cited by
- 875
- References
- 109
- Citations by year
- 2026: 73 · 2025: 112 · 2024: 121 · 2023: 118 · 2022: 153 · 2021: 157 · 2020: 98 · 2019: 35 · 2018: 8
- Type
- posted content
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- U.S. Department of Defense
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- National Science Council
- National Institutes of Health (5r01ca042978-30)
- National Cancer Institute (CA042978, CA203657, P01CA203657, R01CA175747, T32CA009156, P50CA196510, R01-CA042978, CA199235, U01CA199235, CA196510, P30CA016086)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS, pancreatic ductal adenocarcinoma, pancreatic cancer, driver mutations, therapeutic target, KRAS inhibitors
- MeSH terms
- Adenocarcinoma, Animals, Humans, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Protein Kinase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
